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Genetic studies have shown that mutations of complement
inhibitors such as membrane cofactor protein, Factors H, I,
or B and C3 predispose patients to atypical hemolytic uremic
syndrome (aHUS). Factor I is a circulating serine protease that
inhibits complement by degrading C3b and up to now only
a few mutations in the CFI gene have been characterized. In a
large cohort of 202 patients with aHUS, we identified
23 patients carrying exonic mutations in CFI. Their overall
clinical outcome was unfavorable, as half died or developed
end-stage renal disease after their first syndrome episode.
Eight patients with CFI mutations carried at least one additional
known genetic risk factor for aHUS, such as a mutation inMCP,
CFH, C3 or CFB; a compound heterozygous second mutation
in CFI; or mutations in both the MCP and CFH genes.
Five patients exhibited homozygous deletion of the Factor
H-related protein 1 (CFHR-1) gene. Ten patients with aHUS had
one mutation in their CFI gene (Factor I-aHUS), resulting in a
quantitative or functional Factor I deficiency. Patients with a
complete deletion of the CFHR-1 gene had a significantly
higher risk of a bad prognosis compared with those with one
Factor I mutation as their unique vulnerability feature. Our
results emphasize the necessity of genetic screening for all
susceptibility factors in patients with aHUS.
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Several studies have emphasized the role of the alternative
complement pathway in the pathogenesis of atypical hemo-
lytic uremic syndrome (aHUS), an uncommon form of
thrombotic microangiopathy.1 Mutations have been identi-
fied in genes encoding fluid-phase complement inhibitors
Factor H (FH), the serine protease (SP) Factor I (FI), as well
as the surface-bound inhibitor membrane cofactor protein
(MCP, CD46) and more recently thrombomodulin and,
in Factor B (FB) and in C3, which are included in
the alternative pathway C3 convertase.2–5 In addition, a few
common complement regulator gene polymorphisms, such
as p.Arg240His in the C4b-binding protein (C4BP) gene
(C4BPA), and deletion of two closely related genes, such as
complement FH-related 1 and 3 (CFHR-1, CFHR-3), or
variants in CFH and MCP genes have been reported to
increase the risk for aHUS.6–8 Recently collected data from
registries allowed a generalized analysis of the clinical
characteristics of aHUS patients according to the identified
risk factors.9,10 Indeed, mutations reported in CFH and MCP
genes account for 20–30 and 10% of aHUS cases, respectively.
Patients with MCP mutations have a good renal prognosis
and are characterized by aHUS that reoccurs frequently in the
native kidney, but not after transplantation, compared with
those with defects in CFH. Several studies reported low
frequency (o5%) of CFI mutations in aHUS, with the
exception of the French cohort of patients with a early onset
of aHUS (12% in a cohort of 46 aHUS with pediatric
onset).9–12 FI is a two-chain SP predominantly synthesized by
the liver, in which the 38-kDa light chain carries the catalytic
domain (SP or SP domain) with the catalytic triad His362,
Asp411, and Ser507,13 although the function of the heavy
chain is unclear. The crucial step of the alternative pathway
activation is the formation of the C3 convertase, an
enzymatic complex composed of C3b and Factor Bb
(C3bBb), which proteolytically activates C3. In the presence
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of FH, C4BP, or MCP as cofactors, FI inactivates C3b by
further proteolytic cleavage yielding iC3b.14 The CFI gene is
located on chromosome 4 and comprises 13 exons.15 Until
now, 17 heterozygous mutations in CFI have been reported in
patients with aHUS, but their functional consequences were
characterized in approximately half of the cases. A summary
of CFI mutations and their functional consequences is
presented in Table 1.9–12,16–21 In some patients, the mutant
FI protein is present in normal amounts, and the presumed
functional deficiency has not yet been defined.16,17,20
We screened 202 patients suffering from aHUS for
CFI mutations, and identified 18 different mutations in
exonic sequences in 23 patients. This study establishes the
high frequency of CFI mutations associated with a second
genetic abnormality or with rare polymorphisms in comple-
ment proteins, which may contribute to the severity
of aHUS in these subjects. Furthermore, using in vitro
expression system and molecular modeling, we identified the
nature of functional defects of eight new mutations in
the CFI gene.
RESULTS
Genetic screening, complement component assessment
Among the 202 aHUS patients included in the current study,
23 (12 women and 11 men) had CFI gene mutations resulting
in a frequency of 11.3% (Figure 1, Tables 2 and 3). None of
the detected mutations were found in 100 healthy indivi-
duals. All mutations were heterozygous except one. Two
patients presented two mutations in the CFI gene (one
compound heterozygous and one homozygous). We identi-
fied 17 missense mutations, one nucleotide deletion leading
to a premature stop codon and one nonsense mutation. Nine
mutations were located within the SP domain. Of the
23 patients, 8 presented low FI concentration at the time of
investigation.
Among the group of patients with CFI mutations,
eight patients carried a single gene mutation in MCP
(n¼ 2), CFH (n¼ 1), CFI (n¼ 1), C3 (n¼ 2), or CFB
(n¼ 1), or with a mutation in both MCP and CFH
genes (n¼ 1). Five patients exhibited homozygous deletion
of the CFHR-1 gene, and one patient had the polymorphism
Table 1 | Summary of mutations and their functional consequences
FI domains References
FIMAC CD5 LDLr Linker Serine protease Original report Functional studies
R299W Caprioli et al.9 Kavanagh et al.17Functional
deficiencya I322T Geelen et al.
18 Kavanagh et al.17
D501N Caprioli et al.9 Kavanagh et al.17
D506V (P22) Fremeaux-Bacchi et al.19 Kavanagh et al.17
I415V (P8) Sellier-Leclerc et al.10 New
Quantitative
deficiency
1446–1450del
TTCAC
Caprioli et al.9 Kavanagh et al.17
W528X Fremeaux-Bacchi et al.19 Fremeaux-Bacchi
et al.19
c.922 delC Kavanagh et al.12 Kavanagh et al.12
c.1624 ins AT Esparza-Gordillo et al.11 Esparza-Gordillo
et al.11
W127X Kavanagh et al.12 Kavanagh et al.17
R456X (P10) Fremeaux-Bacchi et al.19 New
I398L (P5;P6) Sellier-Leclerc et al.10 New
C25F (P1) N133S (P3) c.784delA
(p.G243fsX46)
(P4, P15)
A413T (P7) New New
P32A (P2;
P11)
W438L (P9) New New
No functional
defect
identified
M120I Kavanagh et al.17 Kavanagh et al.17
G243D (P16;
P17)
Nilsson et al.16 Nilsson et al.16;
Kavanagh et al.17
Undetermined A222G Caprioli et al.9
Y369S Chan et al.20
H165R (P14) Sellier-Leclerc et al.10; Boyer
et al.21
Gly101R (P12) D385N (P19) New
His100R (P13) I288S (P18) G406D(P12) New
Y441S (P21) New
P535S (P23) New
Abbreviations: FI, Factor I; FIMAC, Factor I membrane attack complex; LDLr, low-density lipoprotein receptor.
Mutations reported in this series are represented in bold.
aDefect in C3b cofactor activity.
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(p.Arg240His) in C4BPA. Of the 13 patients, 4 presented low
C3 levels at the time of investigation. Overall, 10 patients
were negative for mutations/deletions in CFH MCP, C3,
CFB, CFHR-1, and C4BPA genes and formed the group of
aHUS-FI patients. In three of these patients, C3 and FB
plasma concentrations were decreased, which is consistent
with alternative pathway activation. C4 and FH were in the
normal range in all patients. Except for one (P17), none of
the patients with a CFHR-1 deletion presented with anti-FH
antibodies.
Clinical outcome of patients with CFI mutations
Of 23 patients with CFI mutations, 3 presented a familial
form. The age at onset varied from neonatal to early
adulthood (Tables 1 and 2). The first episode of aHUS
occurred at o2 months of age in four patients. All patients
but one exhibited acute renal failure (defined as an acute
increase in the serum creatinine level from the baseline level).
None of the patients in the aHUS-FI group, except one,
presented a severe initial outcome defined by end-stage renal
disease (ESRD) or death 1 year after the onset. Patient 6, who
presented severe facial malformed syndrome, died a few days
after the onset. Three patients from this group were on
chronic dialysis 18 months, 2 years, or 12 years, respectively,
after the first flare. No relapse occurred during the follow-up
for five patients. In the group of patients with additional
genetic defects in complement genes, 10 out of 13 presented a
severe outcome. Patient 16 died from Staphylococcus aureus
septicemia.10 Five patients had ESRD as soon as the first
episode of the disease, and three had a rapid evolution to
ESRD during the first year after the onset. Kaplan–Meier
curves suggested longer overall kidney function among
patients with exclusively CFI mutations than among those
with CFI mutations associated with a deletion of the CFHR-1
gene (P¼ 0.006 by log-rank test) (Figure 2).
Analysis of the consequences of mutations on recombinant
CFI expression and processing
The impact of CFI mutations found in aHUS-CFI patients
(that is, those lacking additional genetic abnormalities) on FI
production and function was assessed using an in vitro
expression model. We first cloned the cDNA coding for
human wild-type (WT) CFI into a eukaryotic expression
vector and transiently expressed the protein in human
embryonic kidney (HEK)293 cells. Both pro-FI and mature
FI were detected in the culture supernatant at day 2 (data not
shown). Mutations were introduced by site-directed muta-
genesis, and their consequences on FI production were
evaluated 2 days after transfection. FI mutant D506V
previously identified to be associated with a functional
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Figure 1 | Schematic localization of CFI mutations identified in
the French cohort. In vitro expression studies in mammalian cells
have been conducted for the underlined mutations. FIMAC, Factor
I membrane attack complex.
Table 2 | Patients with CFI mutations
CFI sequence change Summary of clinical history and biological findings
Numbering
Patients
Genetic
status
Nucleotide
from ATG
Nucleotide
from Met1
Nucleotide from
mature protein
C3
(mg/l)
FB
(mg/l)
FI
(mg/l) S/F
Age of
onset
ESRD or death
1 year after the onset Late outcome
P1 Het c.128G4T p.Cys43Phe C25F 704 107 40 S 30 No ESRD (12 y)
P2 Het c.148C4G p.Pro50Ala P32A 777 129 40 S 0.04 No No relapse (6 y)
P3 Het c.452A4G p.Asn151Ser N133S 583 80 23 S 39 No No relapse (4 y)
P4 Het c.784delA c.784delA
(p.G243fsX46)
891 104 28 S 32 No ESRD (18 m)
P5 Het c.1246A4C p.Ile 416Leu I398L 1030 ND 43 S 0 No No relapse (6 y)
P6 Het c.1246A4C p.Ile 416Leu I398L 410 67 ND S 0.08 Death
P7 Het c.1291G4A p.Ala431Thr A413T 857 139 44 S 18 No Relapses (2, 3, and 8 m)
and ESRD (2 y)
P8 Het c.1297A4G p.Ile433Val I415V 1000 190 112 S 0.16 No No relapse (10 y)
P9 Het c.1367G4T p.Trp456Leu W438L 738 128 20 S 22 No No relapse (5 y)
P10 Het c.1420C4T p.Arg474Stop R456X 601 55 24 S 31 No Relapses (2, 4 m)
and ESRD (18 m)
Abbreviations: aHUS, atypical hemolytic uremic syndrome; CFI, complement Factor I; ESRD, end-stage renal disease; F, familial aHUS; FB, Factor B; FI, Factor I; m, month;
ND, not determined; S, sporadic aHUS; y, year.
Individual clinical histories have been previously reported for four patients (P2, P5, P8, and P10).10,19
Normal values: C3 (660–1275mg/l); FI (42–78mg/l); FB (42–78mg/l). ESRD was defined as the need for chronic renal replacement.
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deficiency was used as a control.17 As shown in Figure 3,
C25F, N133S, I398L, A413T, and W438L mutations led to a
dramatic decrease in the FI level detected in cell culture
supernatants by enzyme-linked immunosorbent assay (ELISA)
and western blotting. The P32A mutation resulted in a 60%
decrease in the FI level in the supernatant. I398L, A413T,
W438L, and P32A mutations reduced the amount of
intracellular FI. As expected, the two mutations predicted
to generate premature stop codon resulted in the absence of
detectable recombinant FI in both the supernatant and the
cell lysate, despite transfection efficiency equivalent to WT.
Only the W438L mutation led to the slightly reduced
electrophoretic mobility of intracellular recombinant FI in
contrast to all the other missense mutations that migrated as
the WT. To further investigate the mechanisms leading to a
decrease in FI secretion, we studied the subcellular localiza-
tion of FI in HEK293 cells transfected with WT, I398L, or
A413T FI constructs. In cells expressing the WT protein,
colocalization of the FI protein with wheat germ agglutinin
was observed, resulting in a dot pattern consistent with a
trans-Golgi localization. In cells expressing either I398L or
A413T mutant FI, there was no colocalization with wheat
germ agglutinin, but instead with protein disulfide isomerase,
a marker for the endoplasmic reticulum (Figure 4). Further-
more, a fraction of intracellular WT FI was resistant to
endoglycosidase H digestion, whereas I398L and A413T FI
were not (data not shown).
Mutations I415V and D506V had no effect on either intra-
cellular or extracellular FI levels. Therefore, we investigated
the functional activity of both mutants produced in vitro.
No differences were detected for their ability to cleave C3b
and C4b in solution as compared with WT (Figure 5). We
also tested the ability of WT D506V and I415V FI to
inactivate membrane-bound C3b in the presence of FH.
We found that WT FI inactivated C3b in a time-dependent
manner. On the contrary, the supernatant of cells transfected
with the I415V mutant was not effective in inactivating
membrane-bound C3b, and the slight decrease in stabilized
C3b sites was comparable with the decrease observed using
the supernatant of mock-transfected cells. The D506V
mutant FI showed a slightly reduced activity (Figure 5c).
Table 3 | Patients with CFI mutations combined with a second genetic abnormality
CFI sequence change Clinical history
Genetic
status
Nucleotide
from ATG
Amino
acid
According to
mature protein
Associated genetic
change
C3
(mg/l)
FB
(mg/l)
CFI
(mg/l) S/F
Age of
onset
ESRD or death
1 year after the onset Late outcome
P11 He c.148C4G p.Pro50Ala P32A MCP (p.Arg103Trp;R69W) 915 176 67 F 2 No Two relapses (5, 7 y)
and lost from follow-up
P12 He c.355G4A p.Gly119Arg G101R CFI (p.Gly424Asp; G406D) 893 129 50 S 42 No No relapse (10 y)
P13 He c.353A4G p.His118Arg H100R MCP (IVS 2+2) 1140 166 71 S 32 Yes (ESRD)
P14 He c.348A4G p.His183Arg H165R CFH (p.Asn767LysfsX7) 290 150 71 S 1.4 Yes (ESRD)
P15 He c.784delA p.G243fsX46 Del CFHR1(HO) 545 72 24 S 31 Yes (ESRD)
P16 He c.782G4A p.Gly261Asp G243D C3 (p.Lys155Gln) 1150 206 76 F 0.5 Death
P17a He c.782G4A p.Gly261Asp G243D Del CFHR1(HO) 694 118 82 S 28 Yes (ESRD)
P18 He c.917T4G p.Ile 306Ser I288S Del CFHR1(HO)
Del CFHR3 (HO) 892 128 77 S 32 Yes (ESRD)
P19 He c.1207G4A p.Asp403Asn D385N Del CFHR1(HO)
Del CFHR3 (HO) 839 99 72 S 43 Yes (ESRD)
P20 Ho c.1246A4C p.Ile 416Leu I398L Del CFHR1(HO)
Del CFHR3 (HO) 523 36 17 S 46 Yes (ESRD)
P21 He c.1376A4C p.Tyr459Ser Y441S CFB ( p.Val455Ile) 1050 46 S Yes (ESRD)
P22 He c.1571A4T p.Asp524Val D506V C3 (p.Pro1114L) 624 76 65 S 1.5 No No relapse (8 y)
P23 He c.1657C4T p.Pro553Ser P535S CFH (p.Arg1210Cys)
MCP (p.Tyr29X)
1260 151 76 F 30 Yes (ESRD)
Abbreviations: CFI, complement Factor I; ESRD, end-stage renal disease; FB, Factor B; FI, Factor I; m, month; y, year.
Individual clinical histories have been previously reported for five patients (P11, P14, P16, P17, and P22).10,16,19,21,25
aThe screening for anti-Factor H for P17 was positive at the diagnosis and during follow-up. Screening for anti-FH antibodies was negative for patients 15, 18, 19, and 20.
Mutations reported in this series are represented in bold.
Normal values: C3 (660–1275mg/l); FI (42–78mg/l); FB (42–78mg/l).
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Figure 2 |Kaplan–Meier curves for kidney survival in patients
with aHUS and CFI mutations. Cumulative fraction of patients
free of events (or overall renal survival), defined as the
combination of the occurrence of initiation of dialysis or death,
whichever occurred in aHUS-CFI patients without additional
genetic defect (aHUS-FI) or with a complete deletion in the CFHR-1
gene (aHUS-FI-del CFHR-1). aHUS, atypical hemolytic uremic
syndrome; FI, Factor I.
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Structural analysis of point mutations
To evaluate the potential consequences of point mutations on
the protein structure, we produced high-resolution homo-
logy models of FI domains (Figure 6) and mapped the
corresponding mutations in appropriate domains. Predicted
consequences of the mutations are summarized in Table 4.
DISCUSSION
This report is focused on aHUS patients carrying mutation in
the CFI gene. Less than 20 cases of patients with aHUS with a
mutation in the CFI gene have been reported previously
(reviewed in Chan et al.20 and Kavanagh et al.22; Table 1),
and the aHUS-phenotype associated with CFI gene muta-
tions appears to be variable in contrast to the cases of FH and
MCP.10 In this study, we report results of CFI genetic
screening in a large cohort of non-Stx–HUS patients.
Mutations in CFI account for 11.3% of aHUS cases in the
cohort of 202 patients, which is slightly higher than the
frequency reported by the other groups.9,12 All CFI mutations
but one are heterozygous and located throughout the entire
gene. Of 10 mutations, 9 that were investigated in depth in
our study led to reduced protein levels in vivo and/or in vitro.
In vivo plasma FI was occasionally detected at normal levels
in patients (or in unaffected relatives bearing the mutation),
although mutations resulted in quantitative defects in vitro.
As previously postulated by Kavanagh et al.,17 our current
results emphasize that the FI level within normal range does
not exclude a mutation impairing FI secretion or produc-
tion.17 We report the first case of homozygous mutation with
a subtotal FI deficiency in an aHUS patient. The correspond-
ing recombinant FI I398L mutant was very weakly secreted
in vitro into the supernatant of transfected cells, explaining
the low concentration of FI in the patient’s plasma. According
to previous reports, patients with complete FI deficiency
have increased susceptibility to recurrent infection.14 The
exceptional association of aHUS in this patient could be
due to the presence of only partial consumptive loss of C3,
in contrast to patients with complete FI deficiency having
undetectable C3 levels.23 Using a membrane-bound C3b
inactivation assay, we identified I415V as a new mutation
associated with functional deficiency. It had similar behavior
as the D506V substitution.17 Hemolytic test demonstrated
a functional defect for these two mutant proteins; however
the A415V mutation carried the more severe defect for these
two mutant proteins. In a different experimental setting of
fluid-phase cofactor assay, mutants were capable of performing
the catalytic act. In these experiments, the FI/FH ratio was
B1/1 (FI was not the limiting factor for the reaction) in an
isotonic buffer (rather than in low ionic strength, characteristic
for the hemolytic test and for the previously published
cofactor activity data for D506V). Under these favorable
experimental conditions, mutant proteins cleaved C3b and
reached the efficiency of the WT. Thus, in corresponding
patients, a partial protection of the endothelium may be
achieved because of reduced, but existing, enzymatic activity of
mutant proteins. Taken together, as reported for aHUS-MCP,
B30% of mutations in the CFI gene result in a functional
deficiency.24
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Figure 3 |Consequences of mutations on FI production. The FI synthesis was assessed 48 h after transfection by ELISA (a) and western
blotting with anti-V5 antibody (b) in cell supernatants and cell lysates. Untransfected (NT) cells were used as negative control.
The membrane used for western blotting was reprobed with anti-tubulin and anti-EYFP antibodies, which served as loading
and transfection controls, respectively. *Significantly different from WT FI level according to Student’s t-test (Po0.05). The results are
representative of three independent experiments, with bars corresponding to s.d. ELISA, enzyme-linked immunosorbent assay; FI, Factor I.
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In general, patients with aHUS have only one discovered
mutation.9 Surprisingly, in the group of patients with CFI
gene mutations, 30% of patients (7 of 23) had an additional
mutation in genes known to represent the susceptibility
factor for aHUS. We identified four patients who presented
with heterozygous quantitative or functional MCP or FH
deficiency. In particular, both R69W and R1210C FH
mutations in MCP and CFH genes, respectively, were
deficient in their ability to control the alternative pathway
on a cell surface.25,26 Patients with simultaneous CFI and
MCP mutations were also reported in other studies.9,11 Three
patients had previously unreported mutations in recently
identified aHUS susceptibility genes C3 and CFB.2,3,27
Further experiments are currently underway to assess their
functional role.
In the current study, 5 out of 23 (21%) patients with the
CFI mutation have no CFHR-1 gene, which appears to be
higher than the number reported in Caucasian control
subjects (between 2 and 7%).28,29 FH-related (CFHR)
proteins share common features with FH, but their exact
functions are unclear, although a general role in the
regulation of complement activation is emerging.29,30 Several
studies support the hypothesis that polymorphisms or
haplotypes in MCP and CFH genes greatly influence
predisposition to aHUS and provide an explanation for the
incomplete penetrance of aHUS in carriers of mutations in
complement proteins.7,31,32 Recently, Zipfel et al.8 showed in
two independent cohorts of aHUS patients that the deletion
of CFHR-1 and CFHR-3 increases the risk of aHUS. However,
the disease risk associated with this deletion has been found
to be restricted to the group of patients with anti-FH
antibodies and interestingly also to the group of patients with
CFI mutations.33
In our series of 23 patients, clinical outcome was
unfavorable with 50% of patients dying or progressing to
ESRD immediately or within 2 years after the first episode of
the disease. However, seven patients presented with complete
remission of the disease without aHUS relapses (30%).
Following these observations, we tried to identify factors,
which may influence the severity of the disease. Despite the
small size of the cohort, our study provides evidence for the
influence of the complement genetic background. Indeed, the
common polymorphism of the CFHR-1 gene (or a gene in
linkage disequilibrium with the CFHR-1 gene) had a
dramatic impact on disease severity. Owing to the small
number of patients with CFIþCFH, CFIþMCP, CFIþCFB
GV PDI-Cy5 MergeWGA-TRITCV5-FITC
MT
WT
I398L
A413T
Figure 4 | Subcellular localization of WT, I398L, and A413T FI. Subcellular localization of FI was studied using confocal microscopy 48 h
after transient transfection. Anti-V5 antibody was used to detect FI. WGA stained trans-Golgi (dot-like juxtanuclear aspect; arrow) and
endosomes (granular aspect), whereas anti-PDI stained endoplasmic reticulum. WT FI colocalized with the marker of the trans-Golgi in a
dot-like aspect, which is consistent with a predominant trans-Golgi localization. I398L and A413T mutant FI proteins did not colocalize with
the trans-Golgi marker but with the endoplasmic reticulum marker. GV, global view using the same amplification in each channel; V5-FITC,
V5 tag marked by fluorescein isothiocyanate; PDI-Cy5, PDI revealed by Cyanin5; WGA-TRITC, WGA revealed by tetramethyl–rhodamine
iso-thiocyanate; MT, mock-transfected cells; WT, HEK293 cells transfected with the WT FI construct; I398L and A413T HEK293 cells
transfected with the corresponding mutated FI constructs. FI, Factor I; HEK293, human embryonic kidney293; PDI, protein disulfide
isomerase; WT, wild type; WGA, wheat germ agglutinin.
344 Kidney International (2010) 77, 339–349
or ig ina l a r t i c l e F Bienaime et al: CFI mutations in aHUS
or CFIþC3 mutations, clinical findings were analyzed
descriptively without statistical comparisons. It is known
that patients with defective MCP have a better prognosis than
do those with dysfunctional FH.9,10 The two patients with
CFI and CFH mutations developed ESRD after the first
episode of the disease. In association with the CFI mutation,
the influence of MCP or C3 mutations on the prognosis
might be variable as half of the patients presented a severe
outcome. Analysis of the clinical history of the patients
suggests that aHUS-associated CFI mutations as sole risk
factors have a good prognosis if there are no severe sequelae
after the first episode. Except recurrences within the first year
after the onset, patients did not present any new episodes
during the long follow-up (on average 6 years). We
demonstrated that all mutations identified in patients
without other genetic abnormalities have consequences on
production/secretion or function of the protein. Our results
illustrate that reduction in FI activity secondary to a
quantitative or a functional defect leads to a ‘mild’
thrombotic process.
There are some limitations to our study that should be
pointed out. The functional study was restricted to 11 out of
19 mutations identified in our population. Only all
mutations found in the aHUS-FI group were included in
the in vitro analysis. Therefore, we can conclude that
mutations in CFI as a single genetic abnormality are related
to the pathophysiology of aHUS. The functional conse-
quences of the nine missense mutations found in association
with another genetic defect in the complement gene remain
speculative. As all genetic changes in CFI may not be
associated with a functional defect, and also because of the
small number of patients with CFH, MCP, FB, or C3
mutations in the cohort, the impact of an additive CFI
mutation on the course of the disease could not be assessed
by our study. For the same reason, the more severe renal
phenotype seen in CFHR-1 patients might be related only to
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Figure 5 | Inactivation of C3b and C4b by WT, I415V and D506V FI. (a) (Representative raw data) and (b) (densitometric quantification):
fluid-phase C4b and C3b degradation assay. Partially purified WT, I415V, D506V, and mock-transfected HEK293 cells (only plasmid, PC) were
assayed for their capacity to degrade C4b and C3b in fluid phase in the presence of C4BP or FH as cofactors. As a negative control
(control), FI was omitted in the incubation mixture and highly purified WT FI (20 mg/ml) was used as positive control (þ control). All
samples containing FI contain C3b degradation products of 43 and 46 kDa, and C4b degradation product C4d. The experiment was
repeated four times. One-way ANOVA tests were performed to test significant differences between WT and plasmid only, I415V or D506V,
*P40.05. (c) The kinetics of C3b inactivation by 120 ng of FI WT (WT100) and 60 ng of FI WT (WT50) was assessed and compared to activities
of FI I415V and FI D506V. No significant activity was observed in the absence of FI (concentrated supernatant of mock-transfected HEK293;
control) and with FI I415V supernatant during 90min of the kinetic experiment. In the presence of FI D506V, the residual C3b decreased
with time but the effect was less pronounced than that for the WT. The results are representative of three independent experiments with
bars corresponding to s.d. ANOVA, analysis of variance; FH, Factor H; FI, Factor I; HEK293, human embryonic kidney293; WT, wild type.
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an undefined functional consequence of the CFI mutation
found in these patients. However, it is unlikely, as the five
patients with CFHR1 deficiency have all different CFI
mutations. Moreover, two of these mutations (I398L and
G243fsX46) lead to quantitative FI deficiency. Finally,
although the high prevalence of CFHR-1 deletion in the
Cys25
Pro32
FIMAC domain
lle415
lle398
Ala143
Active site
Pro535
Serine protease domain
Asp506
Trp438
Met120
CD5 domain
Asn133
His165
Figure 6 |CFI homology models. Mutations identified in patients were mapped onto the 3D structures (ribbon rendering generated with
ICM Molsoft (La Jolla, CA, USA), colored from blue, N terminus to red, C terminus) and are shown as CPK spheres (yellow). (a) FIMAC domain;
(b) CD5 domain; (c) serine protease domain. CFI, complement factor I; CPK, Corey-Pauling-Koltun; FIMAC, Factor I membrane attack
complex; 3D, three dimensional.
Table 4 | Structural analysis of the identified point mutations and summary of functional significance
Missense
mutation Domain Location in the 3D models Possible structural/functional impacts Summary
C25F FIMAC Intra-domain disulfide bond Stability/folding problems Quantitative deficiency
P32A FIMAC Turn Solvent exposed
Stability/folding problems
Quantitative deficiency
N133S CD5 a-Helix Solvent exposed
Stability/folding problems through quality-control
mechanisms and/or inter-domain interactions
Quantitative deficiency
I398L SP b-Strand near
a-helix and C terminus
Buried, formation of a small buried cavity most likely
destabilizing the structure by 2–4 kcal/mol
Stability/folding problems
Quantitative deficiency
A413T SP b-Strand Buried, creation of steric clashes that may not be well
tolerated in a buried and tightly packed environment43,44
Quantitative deficiency
I415V SP b-Strand Buried, creation of a small cavity, can potentially modify the
orientation of the catalytic Asp 411
Functional deficiency
W438L SP Loop Solvent exposed
Stability/folding problems through quality-control mechanisms
and/or inter-domain interactions
Quantitative deficiency
Abbreviation: 3D, three dimensional; FIMAC, Factor I membrane attack complex.
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aHUS-CFI population may reflect an impact of this genetic
variant on the penetrance of the disease, the severe course in
these patients may have also influenced their recruitment in
our cohort and may explain the threefold higher prevalence
of CFHR-1 deficiency in CFI mutant aHUS patients.
Our findings establish that a deficiency in the CFI gene
itself has a key role in the development of the disease
and seems to have a specific phenotype. Our data suggest
that the complement genetic background might explain the
variability of the expression of the disease in aHUS patients
with the CFI mutation, and emphasize the necessity to per-
form screening for CFHR-1 deletion and for a second genetic
abnormality in patients with mutations in the CFI gene.
MATERIALS AND METHODS
Clinical and biological screening
We studied 202 patients with aHUS (21 familial and 181 sporadic
forms) referred from several Departments of Nephrology across
France. We report 23 patients from this series, who were screened for
mutations in CFH, CFI, MCP, CFB, and C3 genes and for
polymorphisms (p.Arg240His in the C4BPA gene and deletion of
the CFHR-1 gene).
Clinical data and results of standard biochemical assays were
collected from each referring unit. Informed consent was obtained
from all patients. The clinical history of 10 out the 23 patients with
CFI mutations has been reported previously.10,16,19,21
Complement assays and genetic screening
Plasma concentrations of FH and FI were measured by ELISA,
whereas concentrations of C4, C3, and FB were determined by
nephelometry (Dade Behring, La Defense, Paris, France).19,34 The
membrane expression of MCP was analyzed on granulocytes from
patients using phycoerythrin-conjugated antibodies (Serotec,
Oxford, UK).35 All exons were sequenced as described previously.19,34,35
The primer sequences for CFH, MCP, CFI, CFB, C3, and C4BPA
genes screening are available from the authors on request. We used
the multiplex ligation-dependent probe amplification reaction for
screening CFHR-1 and CFHR-3 genes using specific CFHR-1 and
CFHR-3 probes (MRC-Holland, The Netherlands). In this study, we
used numbering starting from the first amino acid of the FI mature
protein lacking signal sequence as previously used for the majority
of CFI mutations.12,17–19,23
CFI cDNA cloning and mutagenesis
Human liver RNA was retrotranscribed using the AMV Kit (Roche,
Mannheim, Germany). CFI cDNA was amplified by PCR (35 cycles:
95 1C 1min, 55 1C 1min, 72 1C 1min) using proofreading
turboPFU DNA polymerase (Stratagene, La Jolla, CA, USA) and
the following primers: 50-GAACACCTCCAACATGAAGC-30 and
50GACATTGTACTGAGAAATAAAAGGCC-30. cDNA was cloned in
pcDNA3.1/V5-His-TOPO (Invitrogen, Paisley, Great Britain, UK)
according to the manufacturer’s recommendations. Point mutations
were introduced by site-directed mutagenesis using the QuikChange
II XL kit (Stratagene). The whole cDNA sequence of all mutants was
verified by sequencing.
Expression analysis of WT and mutant FI proteins
Human embryonic kidney293 cells were seeded at 1 106 cells in
Dulbecco’s medium supplemented with 5% fetal calf serum. The
next day, transient transfections were carried out with 2 mg of
expression vectors encoding the WT or various mutants of FI
together with 0.03 mg of green fluorescent protein expression vector
(transfection control) using the FUGENE6 transfection reagent
(Roche). Forty-eight hours after the transfection, supernatants were
collected and cells were lysed in 50 ml of lysis buffer (1% Triton
X100, 10mM Tris-HCl). Transfection efficiency was assessed by
measuring green fluorescent protein expression in cell lysates by
flow cytometry and western blotting, using anti-tubulin and anti-
EYFP antibodies. Independent experiments were repeated thrice.
Stable transfectants of FI WT, I415V, and D506V HEK293 cells were
obtained by selection with 0.6mg/ml geneticin (Invitrogen). The
quantity of FI in the supernatants was determined by ELISA using
sheep anti-FI (Abcam, Paris, France).
Immunofluorescence
Human embryonic kidney293 cells were transfected as described
above and grown for 48 h on microscope cover slips in the culture
medium. After fixation in phosphate-buffered saline–4% parafor-
maldehyde for 15min, cells were permeabilized for 5min in
phosphate-buffered saline with 0.1% Triton X-100 and washed
twice for 5min in phosphate-buffered saline containing 1% fetal calf
serum. Cells were incubated for 45min at room temperature with
mouse anti-protein disulfide isomerase monoclonal antibody
(Abcam) in phosphate-buffered saline–1% fetal calf serum. After
washes, cells were first incubated with Cyanin 5-conjugated anti-
mouse antibody (Jackson Immunology, West Grove, PA, USA) and
tetramethylrhodamine iso-thiocyanate-conjugated wheat germ
agglutinin (wheat germ agglutinin, Sigma, St Louis, MO, USA) for
45min at room temperature, and then with mouse fluorescein
isothiocyanate-conjugated anti-V5 monoclonal antibody (Invitro-
gen) for 45min at room temperature. Slides were mounted with
Vectashield (AbCys, Paris, France) and analyzed by laser-scanning
confocal microscopy (Zeiss LSM 510, Zeiss, Le Pecq, France).
Recombinant CFI purification and fluid-phase C3b and C4b
inactivation assay
Media from cells stably transfected with FI WT, mutants, or mock-
transfected cells were collected, centrifuged, and filtered before
loading on a HiTrap chelating HP 5ml column (GE Healthcare,
Uppsala, Sweden). The column was washed with 20mM sodium
phosphate buffer containing 500mM NaCl, pH 7.4, and the protein
was eluted with 20mM sodium phosphate, 500mM NaCl, and
500mM imidazole pH 7.4. Fractions containing FI were pooled and
dialyzed against Tris-buffered saline pH 8.0 overnight. FI mutants
were only partially purified and their concentrations were measured
by ELISA.19
Factor I (8 mg/ml) was mixed with 50 mg/ml C4b or 150 mg/ml
C3b, 100 mg/ml C4BP or 5 mg/ml FH, and trace amounts of
125I-labeled C4b or C3b in Tris-buffered saline. As a negative
control (control), FI was omitted in the incubation mixture and
WT FI (20 mg/ml) was used as positive control (þ control). The
samples were incubated for 3 h at 37 1C, and the reaction was
terminated by addition of SDS-PAGE sample buffer with reducing
agent (dithiothreitol). The samples were then incubated at 95 1C for
3min and applied on a 10–15% gradient SDS-PAGE. Separated
proteins were visualized and quantified using a PhosphorImager
(Molecular Dynamics, Uppsala, Sweden). The intensity of the
a-chain and the C4d fragment of C4b and the a-chain and the
43-kDa fragment of C3b were analyzed using ImageGauge (FujiFilm,
Tokyo, Japan). The experiments were conducted four times.
Kidney International (2010) 77, 339–349 347
F Bienaime et al: CFI mutations in aHUS o r ig ina l a r t i c l e
Membrane-bound C3b inactivation assay
Modified hemolytic assay was used to assess human plasma FI and
cell supernatants for their capacity to degrade C3b to iC3b in the
presence of CFI-depleted plasma. Sheep erythrocytes (E) sensitized
with antibody (Sigma) and bearing C3b (EAC43b) were prepared as
described previously.36 Approximately 107 EAC43b were incubated
in gelatin veronal buffer-EDTA (75mM NaCl) containing concen-
trated supernatants with various FI mutants and FI-deficient plasma
providing FH as the cofactor. We used plasma samples obtained
from a patient who carried two heterozygous mutations in the CFI
gene leading to a complete FI deficiency. All mutants were used at
the same concentrations as assessed by FI ELISA. At time intervals,
100ml samples were removed, centrifuged, and 100 ml of DGVBþ þ
were added to the pellet of cells. Under these experimental
conditions, EC3b cells were converted to EC3bi in the presence of
functional FI. To each sample, 100 ml of DGVBþ þ containing FB
(0.15mg) and Factor D (0.04 mg) were added for 30min at 30 1C to
form the C3bBb convertase. Lytic sites were developed by adding
300ml of rat serum dilute 1:20 in gelatin veronal buffer-EDTA.
Activity determinations obtained by titration were expressed as the
average number of hemolytic sites per cell (Z). The capacity to form
the C3 convertase at each time point was directly related to the input
of residual erythrocyte-bound C3b. The percentage of residual C3b
was calculated on the basis of complete lysis at the beginning of the
kinetic experiment.
Construction of the three-dimensional, homology-based
model of CFI
Three-dimensional models of human FI domains were built on a
Silicon Graphics workstation (Silicon Graphics, Fremont, CA, USA)
using the molecular modeling package Insight II (MSI) and the
modules Homology, Biopolymer, Discover, and CHARMm.37 In
addition, the Loopy program was used to predict insertion loops.38
Multiple sequence alignments and building of the initial structural
models were performed using Homology. Different experimental
structures were used and downloaded from the Protein Data Bank;
the follistatin domain of the human osteonectin crystal
(1bmo.pdb)39 was used for constructing the Factor I membrane
attack complex (FIMAC) domain (S24-T89), the human Mac2-
binding scavenger receptor crystal (1by2.pdb)40 for the CD5 domain
(A90-A201), the human urokinase-type plasminogen activator
crystal (1lmw.pdb),41 for the SP domain (C309-I316 and I322-
G556), and the human coagulation Factor VII (1jbu.pdb)42 for the
C-terminus region (R557-V565) of the SP domain. The sequence
identity between FI domains and the templates was 35–40% with few
insertions/deletions, allowing for accurate homology modeling
experiments. The three-dimensional models were refined with
Discover and CHARMm.43,44
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